Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Adenocarcinoma
66%
Angiography
33%
Bone Scintigraphy
33%
Brain Metastasis
75%
Cancer
33%
Cardiac Magnetic Resonance Imaging
33%
Central Nervous System
33%
Computer Assisted Tomography
66%
Coronary Angiography
33%
Coronary Artery Anomaly
33%
Cryptorchism
33%
Cyst
33%
Diagnostic Criterion
33%
Diseases
44%
Ganglioglioma
66%
Gastrojejunostomy
33%
Gastropexy
33%
Gastrostomy
33%
Hansen's disease
33%
Head and Neck Metastasis
33%
Hip Pain
33%
Hypophysitis
33%
Immune Checkpoint Inhibitor
33%
Ipilimumab
40%
Kidney Tumour
33%
Left Ventricular Hypertrophy
38%
Magnetic Resonance Cholangiopancreatography
33%
Magnetic Resonance Imaging
95%
Malignant Neoplasm
42%
Melanoma
66%
Meningeal Carcinomatosis
33%
Metastatic Carcinoma
75%
Mirizzi's Syndrome
33%
Multidetector Computed Tomography
100%
Myocardial Bridge
33%
Nivolumab
33%
Overall Survival
89%
Parinaud's Syndrome
33%
Pediatrics Patient
42%
Pelvis
33%
Polycystic Kidney Disease
100%
Progression Free Survival
60%
Prostate Cancer
33%
Salivary Duct Carcinoma
33%
Seminoma
33%
Stereotactic Radiosurgery
100%
Systemic Therapy
66%
Tumor
33%
Vascular Pedicle
33%
Von Ebner Gland
33%
Keyphrases
7T MRI
33%
Adenocarcinoma
33%
Adenocarcinoma Not Otherwise Specified
33%
Brain Metastases
41%
Cabazitaxel
33%
Carboplatin
33%
Clinical Features
33%
Computed Tomography
56%
Computed Tomography Diagnosis
33%
Coronary Artery Anomaly
33%
CT Images
36%
Echo Image
33%
Fine-needle Aspiration
33%
Gene mutation
33%
Gradient Echo
33%
Hepatocellular Cancer
33%
High-grade Glioma
66%
Immune Checkpoint Inhibitor-related Hypophysitis
33%
Intracranial Metastases
33%
Ipilimumab
41%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Mirizzi Syndrome
33%
MR Cholangiography
33%
Multidetector Computed Tomography
66%
Myocardial Bridging
33%
Neck Metastasis
33%
Nivolumab
33%
Objective Response Rate
44%
Overall Survival
75%
PALB2 Gene
33%
Palliative Systemic Therapy
33%
Patient Outcomes
41%
Pediatric Patients
42%
Pedicle Sign
33%
Pelvis
33%
Pembrolizumab
33%
Progression-free Survival
56%
Prospective Survey
33%
Salivary Duct Carcinoma
33%
Same-day Pegfilgrastim
33%
Single Center
33%
Stereotactic Radiosurgery
100%
Survey-based
33%
Systemic Therapy
58%
T1-weighted
33%
Tectal Glioma
33%
Treatment Outcome
33%
Treatment Patterns
33%
Tumor
38%
Von Ebner's Gland
33%
